CVD

LIB Therapeutics Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep, a Novel Third-Generation PCSK9 Inhibitor in Development for Cardiovascular Disease

Retrieved on: 
Tuesday, November 14, 2023

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very high and high risk of cardiovascular disease (CVD), today announced completion of LIBerate-CVD and LIBerate-HR, the final two registration-enabling Phase 3 trials for patients with CVD or at very high and high risk of CVD.

Key Points: 
  • LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very high and high risk of cardiovascular disease (CVD), today announced completion of LIBerate-CVD and LIBerate-HR, the final two registration-enabling Phase 3 trials for patients with CVD or at very high and high risk of CVD.
  • These two trials are part of the registration-enabling Phase 3 LIBerate Program which includes four key studies of 2,387 patients dosed for up to 52 weeks, with >2,200 patients continuing in an open-label extension study of 72 weeks.
  • “The global Phase 3 LIBerate program for Lerodalcibep is a large and comprehensive registration-enabling package and includes a diverse global population of patients with CVD, without CVD but at very high and high risk for CVD, and heterozygous and homozygous familial hypercholesterolemia (FH) which should support a broad label upon approval,” said David Kallend, MBBS, Chief Medical Officer of LIB Therapeutics.
  • “We look forward to working with regulators to submit a biologics license application to the Food and Drug Administration and marketing authorization application to the European Medicines Agency in 1H 2024.”

Front End of the Line Semiconductor Equipment Market size to increase by USD 7.56 billion from 2023 to 2028 | Allwin21 Corp., Applied Materials Inc., ASML and more among key companies- Technavio

Retrieved on: 
Thursday, December 14, 2023

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The front end of the line semiconductor equipment market is expected to grow by USD 7.56 billion from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The front end of the line semiconductor equipment market is expected to grow by USD 7.56 billion from 2023 to 2028.
  • The growth of the advanced consumer electronics industry is notably driving the front-end of the line semiconductor equipment market.
  • Front End Of The Line Semiconductor Equipment Market 2024-2028: Company Analysis
    Applied Materials Inc.: The company offers front end of the line semiconductor equipment such as Endura, Alta, Axcela, Aera4, and Aeris-S.
  • View PDF Free Sample Report
    Front End Of The Line Semiconductor Equipment Market 2024-2028: Key Highlights
    The US - semiconductor capital spending market size is estimated to grow at a CAGR of 5.31% between 2023 and 2028.

The American Diabetes Association Releases the Standards of Care in Diabetes--2024

Retrieved on: 
Monday, December 11, 2023

ARLINGTON, Va., Dec. 11, 2023  /PRNewswire/ -- Today, the American Diabetes Association® (ADA) released the Standards of Care in Diabetes—2024 (Standards of Care), a set of comprehensive and evidence-based guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest scientific research and clinical trials. It includes strategies for diagnosing and treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated comorbidities like cardiovascular disease (CVD) and obesity, and therapeutic approaches aimed at minimizing complications and enhancing health outcomes.

Key Points: 
  • "The latest ADA guidelines present pivotal updates for health care professionals, ensuring comprehensive, evidence-based care for diabetes management.
  • "The ADA's Standards of Care ensures health care professionals, especially our primary care workforce, provide the best possible care to those living with diabetes."
  • The Standards of Care are critical to ensuring the improved treatment of diabetes, a chronic disease that requires continuous care through a well-informed and coordinated health care team.
  • Today, the Standards of Care in Diabetes—2024 is available online and is published as a supplement to the January 2024 issue of Diabetes Care® .

Global Cardiology IT Workflow Solutions Business Report 2023: A $969 Million Market in 2022 - Forecast to 2030 - What to Expect in the Market in the Post COVID-19 Period

Retrieved on: 
Thursday, November 30, 2023

Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Key Points: 
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
    Growing Reliance on IT for Clinical Management of Patient Data Brings Cardiology IT Workflow Solutions into a Mainstream Technology in Cardiology Departments Worldwide: Global Spending on Healthcare IT (In US$ Billion) for Years 2021, 2023, 2025 and 2027
    Digitalization to Revolutionize Healthcare & Boost the Role of IT in care Delivery & Management: Global Opportunity for Digital Health (In US$ Billion) for Years 2021, 2023, 2025 and 2027
    Rising Global Burden of Cardiovascular Diseases, Despite Efforts Aimed at Prevention, to Spur Growth in the Market
    Robust Spending on Heart Disease Diagnosis & Treatments Strengthens the Business Case for Investments in Cardiology IT Workflow Solutions: Annual Medical Cost of Cardiovascular Diseases (CVD) in the United States for Years 2020, 2025, 2030 and 2035 (In US$ Billion)

Increasing Wages Will Lead to Healthier Work and Healthier Workers

Retrieved on: 
Wednesday, November 29, 2023

LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The Healthy Work Campaign applauds California for leading the way in 2023 to ensure fair, living wages for healthcare and fast-food workers.

Key Points: 
  • LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The Healthy Work Campaign applauds California for leading the way in 2023 to ensure fair, living wages for healthcare and fast-food workers.
  • California has recognized that, due to wage stagnation and inflation, the living standard of low-income workers has been in decline for many years.
  • The Healthy Work Campaign has reported previously about the contribution of poor working conditions (including low wages) to the health of workers, especially those without a 4-year college degree, which includes fast-food workers and some healthcare support workers .
  • The Healthy Work Campaign urges other states to follow California's lead, to improve economic justice and the health of low-income workers throughout the U.S.

International Trade Commission Makes Affirmative Preliminary Determination in Trade Cases on Aluminum Extrusions from China, Wiley Rein LLP Reports

Retrieved on: 
Friday, November 17, 2023

The cases allege that unfairly dumped and subsidized imports of aluminum extrusions are injuring the domestic industry.

Key Points: 
  • The cases allege that unfairly dumped and subsidized imports of aluminum extrusions are injuring the domestic industry.
  • "Today's vote by the Commission takes the domestic industry one step closer to restoring a level playing field to the U.S. aluminum extrusions market."
  • The Commission's affirmative preliminary injury determination paves the way for the Commerce Department to move forward with its investigations.
  • Commerce is expected to issue its preliminary CVD determination in December 2023 and its preliminary AD determination in March 2024.

US Department of Commerce Initiates AD/CVD Investigations & ASPA Witnesses Testify at ITC Preliminary Conference

Retrieved on: 
Thursday, November 16, 2023

ASPA also submitted support forms for three non-ASPA processors, and AHSTAC filed its own support forms for nearly 50 boats and six processors.

Key Points: 
  • ASPA also submitted support forms for three non-ASPA processors, and AHSTAC filed its own support forms for nearly 50 boats and six processors.
  • Commerce will now determine whether imported shrimp from the subject countries is being dumped and/or illegally subsidized.
  • ASPA expects Commerce to issue preliminary findings and potential preliminary CVD margins by March 2024 and AD margins by May 2024.
  • We are thankful to Commerce for initiating the investigations and to the ITC for allowing us to present a case on behalf of the entire shrimp industry."

Global Graphene and 2D Materials Research Report 2024-2034: Emerging Applications in Quantum Dots and Fuel Cells

Retrieved on: 
Wednesday, November 15, 2023

The Global Market for Graphene and 2D Materials 2024-2034 stands as the most comprehensive and current report on graphene and 2D materials available today.

Key Points: 
  • The Global Market for Graphene and 2D Materials 2024-2034 stands as the most comprehensive and current report on graphene and 2D materials available today.
  • Emerging applications of graphene, such as quantum dots, fuel cells, filtration, coatings, polymer composites, and lubricants, are examined in-depth.
  • The Global Market for Graphene and 2D Materials 2024-2034 contains:
    Assessment of graphene by market including applications, key benefits, market megatrends, market drivers for graphene, technology drawbacks, competing materials, potential consumption of graphene to 2034 and main players.
  • Assessment of graphene materials (CVD graphene, graphene nanoplatelets, graphene oxide, etc), intermediate products (graphene masterbatches, dispersions, etc) and final products with graphene embedded (e.g.

Pure Storage Drives Global Customer Breakthroughs with Enterprise-Scale AI Initiatives

Retrieved on: 
Monday, November 13, 2023

SANTA CLARA, Calif., Nov. 13, 2023 /PRNewswire/ -- Pure Storage® (NYSE: PSTG), the IT pioneer that delivers the world's most advanced data storage technology and services, today further strengthened its portfolio for artificial intelligence (AI) use cases and continued customer momentum across global AI deployments. Among the first enterprise data storage vendors to receive the NVIDIA DGX BasePOD certification, and now delivering with Cisco, new Cisco Validated Designs for FlashStack for AI, Pure Storage continues to provide enterprises with efficient, reliable access to data in support of new AI applications, underpinning modern, scalable business outcomes.

Key Points: 
  • With NVIDIA DGX BasePOD certification and expanded enterprise AI solutions, Pure Storage delivers simplified and efficient AI-ready storage infrastructure
    SANTA CLARA, Calif., Nov. 13, 2023 /PRNewswire/ -- Pure Storage® (NYSE: PSTG), the IT pioneer that delivers the world's most advanced data storage technology and services, today further strengthened its portfolio for artificial intelligence (AI) use cases and continued customer momentum across global AI deployments.
  • Powering the most advanced AI projects globally, Pure Storage empowers customers to launch AI initiatives at any scale, providing a flexible data storage foundation that grows as needs evolve.
  • Critical advancements to the Pure Storage portfolio include:
    AIRI®: Pure Storage has been at the forefront of optimized AI storage since the launch of FlashBlade® in 2017 and AIRI, its AI-Ready Infrastructure reference architecture co-developed with NVIDIA, in 2018.
  • Pure Storage offers the efficient, high performance storage platform required for AI that is automated, future-proof, and adaptable to evolving needs, catering to a broad spectrum of high-performance AI requirements.

AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023

Retrieved on: 
Friday, November 10, 2023

THOUSAND OAKS, Calif., Nov. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia. These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C). Amgen will also present new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering RNA (siRNA) olpasiran that will focus on a primarily genetically determined and presumed independent CVD risk factor, lipoprotein(a) [Lp(a)].1,2,3,4,5

Key Points: 
  • These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C).
  • Amgen also shared new research from the OCEAN(a)-DOSE study on Lp(a) involving its investigational olpasiran.
  • Additional research presented at AHA will include Mass General Brigham Lp(a) registry data on whether the association between Lp(a) and major adverse cardiovascular events (MACE) differs based on baseline ASCVD status.
  • Amgen will reconvene the LDL-C Action Summit and the newly formed LDL Awareness to Action Implementation Consortium ahead of AHA.